You are correct in that biotechs lose money due to R and D and no income. However, once the product is approved the burn rate will substantially decrease. If you look at my assumptions you will notice a net margin of 50% so I have accounted to expenses related to marketing, supporting and managing product sales. Insurance companies are very sharp when it comes to approving a treatment or not. They will see how much their current cost of therapy is for a patient, for refract gout it can be very high.